Integrin Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4000
$ 6600
$ 8900

Integrins, a diverse family of cell adhesion molecules, are crucial mediators in numerous cellular processes by facilitating interactions between cells and the extracellular matrix. These cell adhesion molecules are present on the cell surfaces of various cell types, including epithelial cells, endothelial cells, immune cells, platelets, and fibroblasts, among others. Integrins are essential for cell-to-cell adhesion, cell-to-extracellular matrix interactions, and signal transduction processes, making them ubiquitous in multiple tissues and organs. Comprised of α and β subunits, integrins bind to specific ligands, such as fibronectin and collagen, initiating intracellular signaling cascades. This conformational change triggers the formation of focal adhesions, stabilizing cell-substrate attachments. Integrins play a pivotal role in diverse physiological and pathological conditions. Promisingly, they are utilized in cancer therapy, where integrin-targeted treatments have shown potential in combating metastasis. Furthermore, integrin antagonists have proven effective in addressing inflammatory disorders, such as rheumatoid arthritis. According to the World Health Organization, cancer remains a leading cause of death worldwide, with approximately 10 million deaths reported annually, highlighting the urgent need for effective integrin-based interventions to combat this devastating disease. Integrins' versatility and their involvement in various health conditions underscore their significance as potential targets for innovative therapeutic approaches. Extensive research is being conducted to find new and novel molecules to prevent and cure disease like Crohn’s disease. The development and launch of newer products by the market players will significantly enhance the revenue of the Integrin market over the forecast years.

A number of these inhibitors are in the market while many are in ongoing clinical trials.  Companies in their pipelines have 104 products in various stages of clinical trials. 3 products are in Phase 4, 6 products in Phase 3 and 4 products are in the Phase 2 of the clinical trials.

Approved molecules

  • Isentress (raltegravir)
  • Entyvio (vedolizumab)
  • Tysabri (natalizumab)

Drugs in Pipeline

  • Cilcane (cilengitide)
  • Entyvio SC (vedolizumab SC)
  • etrolizumab (RG7413)
  • Abegrin (etaracizumab)
  • volociximab (M200)
  • abituzumab (EMD 525797)
  • firategrast (SB683699)
  • Ossirene (AS101)
  • bexotegrast (PLN-74809)
  • E7820
  • Luminate (risuteganib)
  • abrilumab (AMG 181)
  • vatelizumab (GBR 500)
  • BG00011
  • milategrast (E6007)
  • GLPG0187
  • MORF-057
  • OTT166
  • PTG-100
  • intetumumab (CNTO 95)
  • AMEP BA 015
  • ASP5094
  • Carogra (carotegrast methyl)
  • GS-1427
  • GSK3008348
  • SAN-300
  • THR-687
  • ABBV-382
  • AJM347
  • AXR-159
  • GB1275
  • IDL-2965
  • Lutetium-177-PEG-αvβ3-IAC
  • MEDI8367
  • NP-011
  • OPC-415
  • OS2966
  • PB006 (natalizumab biosimilar)
  • PB016 (vedolizumab biosimilar)
  • PF-06940434
  • PN-943
  • R 1541
  • SGN-B6A
  • TRK-170
  • VAX014 intratumoral
  • VAX014 intravesicular
  • VIP236
  • VPI-2690B
  • fluorobenzyl polyethylene glycol mono-triazole tetraiodothyroacetic acid (fb-PMT)
  • transferrin-tumstatin (OCU200)

Clinical Activity and Developments of Integrin

As of July 2023, 104 products for 378 diseases are in clinical trials. For instance,

  • McMaster University is conducting a Phase 4 clinical trial to study combination therapy with Fecal Microbiota Transplantation and Vedolizumab for induction of Ulcerative Colitis that was expected to complete by June 2023.
  • In May 2023, Universiteit van Amsterdam (AMC-UvA) conducted a Phase 4 clinical trial to evaluate the efficacy of early vs. late use of Vedolizumab in Crohn's Disease:
  • Regina Radner Berkovich, Berkovich, Regina MD, Ph.D. Inc is conducting a Phase 4 clinical trial to characterize the biological effect of a pre-planned 12-week dose interruption of Natalizumab that was expected to complete by December 2021.

Molecule name

Number of studies

Entyvio (vedolizumab)


Tysabri (natalizumab)


Isentress (raltegravir)


Entyvio SC (vedolizumab SC)


Cilcane (cilengitide)


Target Indication Analysis of Integrin

Integrins find applications in various medical indications, offering potential therapeutic benefits in various disease contexts. One prominent area where integrin-targeted therapies have shown significant promise is cancer treatment. By inhibiting specific integrins involved in tumor growth and metastasis, these therapies aim to impede cancer progression. Additionally, integrin antagonists have been explored for their potential in treating autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, by modulating immune responses. Integrin-based interventions have also been investigated for their potential to address fibrotic diseases, such as pulmonary and liver fibrosis, where aberrant tissue remodeling occurs. Furthermore, integrins play a crucial role in angiogenesis, making them attractive targets for anti-angiogenic therapies to hinder blood vessel formation in diseases like age-related macular degeneration and solid tumors. With their involvement in platelet function and thrombus formation, integrins are being explored as targets for antiplatelet therapies to prevent cardiovascular events. Collectively, these diverse indications highlight the wide-ranging potential of integrin-based therapies in addressing critical diseases and improving patient outcomes.

Frequently Asked Questions

Isentress (raltegravir), Entyvio (vedolizumab), and Tysabri (natalizumab) are approved by the FDA.

These are being used in various indications like Inflammatory Bowel Disease (IBD), Crohn’s Disease (CD), Ulcerative Colitis (UC), Autoimmune diseases, and others.

Takeda Pharmaceutical, Biogen, Royalty Pharma, Iceni Pharmaceuticals, and Roche are some of the major market players for Integrin.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to different types of disorders like Ulcerative Colitis and Inflammatory Bowel Disease are the key opportunities for Integrin in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  •  Takeda Pharmaceutical
  •  Biogen
  •  Royalty Pharma
  •  Iceni Pharmaceuticals
  •  Roche
  •  AbbVie
  •  EMD Serono Inc
  •  SFJ Pharmaceuticals
  •  Cassiopea S.P.A.
  •  Feramda Pharma Group
  •  Pliant Therapeutics
  •  Allegro Ophthalmics
  •  Amgen Inc
  •  AstraZeneca
  •  Glenmark
  •  Galapagos NV
  •  Morphic Therapeutics
  •  OcuTerra Therapeutics
  •  Protagonist Therapeutics
  •  J&J
  •  Onxeo SA
  •  Astellas Pharma
  •  Kissei Pharmaceuticals
  •  Gilead Lifescience
  •  GSK
  •  Bausch Health
  •  Oxurion NV
  •  AbbVie
  •  Eisai
  •  AxeroVision
  •  Gossamer Bio
  •  Indalo Therapeutics

Adjacent Markets